| Description |
C-82 is a second-generation specific CBP/β-catenin antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
|
| Related Catalog |
|
| Target |
CBP/β-catenin[1]
|
| In Vitro |
C-82 is an active form of PRI-724. C-82 inhibits the activation of isolated primary mouse quiescent hepatic stellate cells (HSCs) and promotes cell death in culture-activated HSCs[1].
|
| In Vivo |
PRI-724 is phosphorylated-C-82 and is rapidly hydrolyzed to its active form C-82 in vivo, and pre-clinical studies have shown a very acceptable toxicity profile[1].
|
| Cell Assay |
The culture-activated hepatic stellate cells (HSCs) are treated with or without C-82 (3, 10 μM) for 5 days. Medium change is not performed after C-82 treatment. Cell viability is examined using XTT based Cell Proliferation Kit[1].
|
| References |
[1]. Osawa Y, et al. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice. EBioMedicine. 2015 Oct 8;2(11):1751-8.
|
